India Joins Health AI Global Regulatory Network

India Joins HealthAI Global Regulatory Network: A Bold Step or a Premature Leap?

On September 5, 2025, India formally became a member of the HealthAI Global Regulatory Network (GRN), joining countries such as the UK and Singapore to develop international standards for Artificial Intelligence (AI) applications in healthcare. While the announcement reflects India's aspiration to shape global ethical norms in AI governance, skepticism lingers over whether domestic preparedness matches global ambition.

The Policy Instrument: HealthAI and India’s Commitments

HealthAI, the Geneva-based nonprofit, serves as the institutional anchor of the GRN, hosting a Global Public Repository of AI-related Registered Solutions for Health. This repository facilitates transparency by documenting registered algorithms that meet international safety benchmarks. Membership grants Indian regulators access to these standards and enables sharing of AI performance data in clinical settings.

The Ministry of Health and Family Welfare, alongside the National Health Authority, has framed this partnership as pivotal in advancing India’s goal to become a global hub for AI talent. The emphasis is clear: attract health-tech startups by enhancing credibility through alignment with international norms. Financial support for these initiatives remains modest; the 2025-26 budget earmarked ₹500 crore under the Ayushman Bharat Digital Mission, less than 2% of its total allocation.

The Case For: Domestic and Global Gains

Advocates argue India stands to benefit significantly across four dimensions:

• Public Health Modernization: AI-driven tools such as disease surveillance systems and telemedicine are indispensable in a nation grappling with a rural health infrastructure deficit. Pilots conducted in Madhya Pradesh have shown that AI-led TB detection systems increase diagnosis accuracy by 28%.
• Global Market Entry: Membership in GRN creates a reputational passport for Indian health-tech startups, easing their entry into stringent markets in Europe and ASEAN. The UK, for instance, barred multiple Indian-developed diagnostic apps in 2023 citing safety concerns. GRN alignment could mitigate such barriers.
• Standards and Oversight: By aligning domestic AI oversight mechanisms with GRN protocols, India could pre-empt unsafe or biased AI models that disproportionately affect marginalized populations. These safeguards echo Europe’s General Data Protection Regulation (GDPR) principles.
• Skilled Workforce Development: In partnership with NASSCOM, the government has pledged reskilling programs for 2 million professionals by 2030 in AI ethics, data science, and algorithmic design.

The framing of India as a global player in responsible AI is appealing. It positions ethical regulation not as a constraint, but as a competitive advantage.

The Case Against: Structural Limitations and Risks

Despite these compelling arguments, India’s plunge into HealthAI raises concerns about readiness. Three glaring weaknesses stand out:

1. Institutional Capacity Weakness: Regulatory bodies such as the Central Drugs Standard Control Organisation (CDSCO) lack specialized expertise in AI governance. Their heavy reliance on external consultants risks reducing oversight to symbolic compliance rather than rigorous enforcement.

2. Data Localization Conflict: Participation in GRN mandates data sharing across borders, but India’s Data Protection Act, 2023 emphasizes localization. This tension complicates deployment and threatens innovation in cross-border diagnostics—particularly for rare diseases requiring global datasets.

3. Algorithmic Bias: The issue of bias in AI models remains unresolved. Studies from the UK’s National Health Service (NHS) found that poorly trained AI exacerbated health inequalities, disproportionately underdiagnosing conditions in minority ethnic populations. India, with its complex stratified demographic, risks amplifying such biases without robust representative datasets.

Moreover, over-regulation may stifle the very startups the government seeks to promote. For instance, Singapore’s health-tech sector benefited from regulatory flexibility, allowing smaller startups to experiment before scaling up. India’s penchant for bureaucratic overreach often kills the innovative spirit at its infancy.

Lessons from International Experience: Singapore’s Pathway

Singapore’s health AI oversight model offers critical lessons. Its regulators adopted a layered approach, introducing a Regulatory Sandbox for startups to test models without immediate compliance requirements. This approach led to rapid incorporation of AI solutions in public hospitals, where over 45% of diagnostic imaging now relies on AI-assisted platforms. Importantly, its decentralized digital health infrastructure—where hospitals independently manage data—avoids the pitfalls India faces with centralized data localization.

However, Singapore's success hinged on high public trust in government agencies, an area where India lags amidst historical concerns over privacy violations in health data-sharing initiatives like Aarogya Setu during COVID-19.

Where Things Stand

The larger question remains whether India can truly capitalize on GRN membership without addressing foundational deficits. Regulatory alignment with GRN protocols may elevate India’s credibility globally, but weak institutional capacity, unaddressed ethical concerns, and conflicting domestic laws weaken the case for immediate benefits.

India’s ambition to lead global health AI governance is bold, but premature without a robust, scalable national infrastructure built on trust, skilled enforcement, and representative data models. For now, the move feels more like strategic signaling than substantive readiness.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions